MRVI Q1 2024 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$64M-18.8% YoY

Gross Profit

$26M40.3% margin

Operating Income

-$19M-29.4% margin

Net Income

-$12M-18.8% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-13.4%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$14M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$667M

Stockholders' Equity

$411M

Cash & Equivalents

$562M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$79M	-18.8%
Gross Profit	$26M	$45M	-43.0%
Operating Income	-$19M	$3M	-844.6%
Net Income	-$12M	-$67,000	-17926.9%

Revenue Segments

Nucleic Acid Production Segment

$46M72%

Biologics Safety Testing Segment

$18M28%

Geographic Segments

North America

$33M52%

Asia Pacific

$21M33%

EMEA

$9M15%

Latin And Central America

$307,0000%